Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user experienced a decrease in libido after long-term use of Finasteride and wonders if it's related to the medication. Responses suggest that hormonal changes and libido fluctuations are normal and may not be solely due to Finasteride.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Phase 3 for PP405 will start in 2027, disappointing many who expected it this year. Some users are trying treatments like topical minoxidil and topical dutasteride while waiting for new developments.

Shedding is a normal part of hair regrowth when using treatments like Dutasteride and Minoxidil, and it can take up to two years for shedding to stabilize and hair to fully recover. Patience is crucial, as initial shedding doesn't mean the treatment isn't working.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The user has been using finasteride and topical minoxidil for 8.5 months, with initial progress slowed due to stopping microneedling. They plan to resume microneedling and consider a hair transplant in the future.

The user has been using oral minoxidil 2.5mg and finasteride 1mg for 3 months and is unsure if they are experiencing hair regrowth or if it's an illusion. Some responses suggest it is regrowth, while others think it's an illusion due to angles and lighting.

The user is using Dutasteride, Minoxidil, microneedling, RU58841, and tretinoin for hair loss. They are experiencing shedding but notice new hair growth and are curious about the timing of future shedding phases.

RU58841 powder may degrade over time, even when stored in a freezer. Users discuss its potential effectiveness after three years of storage.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The user has been using finasteride and dutasteride for six months, experiencing a complete stop in hair shedding but minimal regrowth. They are considering adding RU58841 for potential regrowth, with advice suggesting patience as significant results often take 12-24 months.

The user has been using minoxidil for almost 6 months and finasteride for almost 4 months, experiencing significant shedding and minimal stabilization. They are considering switching to dutasteride if no improvements are seen and are advised to be patient, as results may take up to 2 years.

A new hair growth drug claims to reverse severe hair loss without using minoxidil, finasteride, or hormone-altering drugs, but many are skeptical due to lack of evidence and concerns about misleading claims. The drug is expected to be released in early 2027, but its legitimacy is questioned.

RU58841 can be absorbed systemically after topical application, but the study did not find immediate hormonal disruption. The study highlights the need for more research on long-term safety and effects of RU58841, as well as the importance of quality control in products from the grey market.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

The conversation is about a user experiencing hair shedding after switching from finasteride to dutasteride and increasing their oral minoxidil dose. The user is advised to continue with the current treatment, consider adding topical minoxidil, and consult a dermatologist for potential underlying issues.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

The conversation discusses the effectiveness of dutasteride and finasteride for hair loss, with the original poster expressing concern over worsening hair loss despite long-term use. Users suggest that if no improvement is seen after 12-18 months, it may be time to reconsider the treatment, and some question the possibility of other underlying causes or the quality of the medication.

Many men learn about finasteride too late for effective hair loss treatment. Early use of finasteride is crucial, but fear of side effects and lack of awareness hinder timely adoption.

The user is experiencing noticeable hair regrowth after almost 60 days of using topical minoxidil and oral finasteride. They are considering whether to buzz their hair to monitor progress or let it grow, and they have not experienced shedding.

The user is experiencing sleep issues after starting finasteride for hair loss and is considering using magnesium or melatonin to improve sleep. Other users suggest that sleep disturbances are a common side effect initially, but may improve over time.

A 26-year-old male started minoxidil treatment for male-pattern baldness and saw significant regrowth in three months. He is considering finasteride but is hesitant due to potential side effects.

The user is using oral finasteride, topical minoxidil, and microneedling for hair loss. Progress has slowed, with the crown showing little change, but the hairline is improving with more thin baby hairs.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

The user switched from topical 5% minoxidil to oral 2.5mg minoxidil for convenience while traveling and is experiencing prolonged shedding, which is causing concern. Community members suggest that shedding can last longer than expected, and some recommend increasing the oral dosage or combining it with topical application for better results.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Applying minoxidil immediately after microneedling at 0.5mm can cause stinging and potential systemic absorption, so some users prefer to wait 12-24 hours. Others report no issues with immediate application, but caution is advised to avoid irritation and side effects.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.